The primary analysis of the phase 2 NEO-MEL-T study (NCT04139902) evaluating the neoadjuvant therapy of dostarlimab (Jemperli) plus the anti-TIM-3 agent cobolimab in high-risk resectable melanoma was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a late-breaking abstract.
Melanoma News
High-fiber diet could improve response to immunotherapy for patients with melanoma
A high-fiber diet increased response to immunotherapy for patients with melanoma compared with a normal healthy diet.
Encorafenib + Binimetinib Displays Promising Safety, Efficacy Signals in BRAFV600E/K–Mutated Melanoma
Treatment with a combined BRAF/MEK–targeted approach previously demonstrated success in stage III/IV melanoma, leading Columbus-AD trial investigators to evaluate encorafenib and binimetinib in stage IIB/C, BRAFV600E/K–mutated disease.
PD-1 Regulates CD30, Curbs T Cell Suppression in Melanoma
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors.